United Kingdom (UK)
Recombinant monoclonal antibody to gHgL. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CL40.
UniProt Accession Number of Target Protein: P03231; P03212
Alternative Name(s) of Target: Envelope glycoprotein H; Envelope glycoprotein L
Specificity: The antibody binds to an epitope in gH D-II that overlaps substantially with a region observed to interact with the gp42 HP. In particular the antibody interacts with gH D-II using light chain contacts composed of L-CDR3 with the N-terminal end of gH:2α-7 (helix 7 in gH:D-II), and L-CDR1 with the loop connecting gH:2α-4 and gH:2α-5. Key residue interactions include hydrogen bonds between gH:D284 and L-CDR3:Y94, gH:E286 and L-CDR3:N92, and the backbone of gH:V243 and L-CDR1:N32. There is also minimal lateral contact with gH D-III between L-CDR1: Q27 and the C-terminal end of gH:3α-6, and VL:D1 with gH:N508 on the other side. The antibody heavy chain contacts with gH include H-CDR2:D52 and H-CDR2:D55, forming salt bridges with gH:R184, and backbone H-bonds between H-CDR3: L100 and H-CDR3:L101 with gH:H239.
Application Notes: The antibody blocks EBV-mediated membrane fusion with both B cells and epithelial cells and it retains its inhibitory activity as a monomeric Fab. Flow cytometry cell counts showed that Fab fragment inhibits virus entry. Neutralization experiments with epithelial cells using an EBV-GFP reporter virus and purified Fab were performed. Fluorescence images obtained at 24 h postinfection and flow cytometry cell counts showed that the Fab inhibits virus entry. Fab inhibition of cell–cell fusion and EBV infection exhibited similar concentration dependence. (PMID: 28939750) The cell-surface expression of gHgL was evaluated using the antibody by CELISA. (PMID: 27929061)
Antibody first published in:
Sathiyamoorthy et al. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8703-E8710. PMID:28939750
Note on publication:
The authors studied the structure and mechanism of anti-gHgL antibody CL40 that blocks membrane fusion with both B cells and epithelial cells.